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Abstract 
BACKGROUND: The pathogenesis of inflammatory neuronal cell damage will continue after traumatic brain injury 
in which contributed to subsequent mortality. Serum S100B levels were shown to be an early predictor of mortality 
due to traumatic brain injury.  
AIM: This Meta-Analysis will analyse the mean and diagnostic strength of serum S100B levels between survived 
and died subjects with head injuries based on the various follow-up times of nine studies.  
METHODS: We conducted a meta-anelysis in accordance with PRISMA guidelines and adhering to Cochrane 
Handbook for Systematic Review of Interventions. Literature search was conducted on March 16, 2018 from 
Medline and Scopus in the past 10 years, using various keywords related to S100, brain injury, and outcome. 
Duplicate journals were sorted out via EndNote. Included articles were as follows: original data from the group, 
clinical trials, case series, patients undergoing serum S100B levels with both short- and long-term follow-up 
mortality. Data were collected for mortality, serum S100B levels, and its diagnostic strength. All data were 
analyzed using Review Manager 5.3 (Cochrane, Denmark). 
RESULTS: The results of the meta-analysis showed a significant difference in S100B levels between survived 
and died subjects with head injuries on overall follow-up timeline (0.91, 95.9% CI 0.7-1.12, I2 = 98%, p < 0.001), 
during treatment (1.43, 95% CI 0.97 to 1.89, I2 = 98%, p < 0.001), or 6 months (0.19; 95%CI 0.1-0.29, I2 = 76%, p 
< 0.001) with an average threshold value that varies according to the study method used. The mean diagnostic 
strength was also promising to predict early mortality (sensitivity of 77.18% and 92.33%, specificity of 78.35% and 
50.6%, respectively).  
CONCLUSION: S100B serum levels in the future will be potential biomarkers, and it is expected that there will be 
standardised guidelines for their application. 
 
 
 
 
Introduction 
 
Traumatic brain injury is a trauma that causes 
abnormal functioning of the brain due to impact or 
blows to the head. Every year, millions of people enter 
the ED due to head injuries, and 1.5 million of them 
die [1]. In Sanglah General Hospital in Denpasar, the 
incidence of annual head injuries averages over 2000 
cases, of which 30% are moderate and severe 
traumatic brain injury patients [2]. Many deaths that 
occur before the patient arrives at the hospital or 
during the period of treatment [3]. However, continued 
inflammatory processes in secondary traumatic brain 
injury [4] cause molecular cell damage, changes in 
metabolism and cerebral blood flow, axonal 
disruption, and apoptosis which contribute to long-
term mortality [5]. Predictors of traumatic brain injury 
mortality such as low Glasgow coma scores, 
unresponsive pupillary reactions, and hemodynamic 
disorders [6] are not quantitative and specific so 
biomarkers are needed to predict mortality in 
traumatic brain injury [7]. Among potential new 
biomarkers, S100B has high specificity for neural 
networks associated with mortality and a prognosis 
that does not benefit [8]. 
S100B is released after brain injury and 
released more as a structural factor (at high 
concentrations) and repair (at low concentrations), so 
it will be very useful in the diagnosis of traumatic brain 
injury [9]. The S100B ability as a predictor of traumatic 
brain injury mortality has been shown in studies, [10] 
[11] [12] some of these studies oppose these results 
[13]. Different results can be due to methodological 
differences, sample size, non-standardized tests, and 
different subject demographics. To further deepen the 
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usefulness of serum S100B levels as a predictor of 
traumatic brain injury mortality, this meta-analysis will 
present an analysis of several studies both S100B as 
a predictor of initial and later mortality.  
This study aims to analyse the difference in 
mean serum S100B levels between patients who died 
or survived traumatic brain injury based on follow-up 
time. 
 
 
Methods 
 
This study presents a meta-analysis of the 
role of serum S100B as a predictor of mortality in 
traumatic brain injury. The study design follows the 
PRISMA guidelines for meta-analysis [13]. The steps 
follow the Cochrane Handbook for Systematic Review 
of Interventions [14] guidelines. 
A comprehensive literature search was 
conducted by the author on March 16, 2018. Relevant 
studies were obtained from Medline (2008-2018) and 
SCOPUS (2008-2018) in the last 10 years. 
References from all studies are further reviewed to 
identify additional relevant research. The author uses 
a search strategy with (((((((((S100B) OR S100) OR 
S-100) OR S-100B) OR S100β) OR S-100β) AND 
((MORTALITY) OR OUTCOME) AND (BRAIN 
INJURY)) AND "last 10 years" [PDat]). 
Duplicate journals are managed using 
EndNote. The title and abstract of the search results 
are reviewed, and the full text is analysed for inclusion 
in this meta-analysis. All articles are assessed using 
the inclusion and exclusion criteria determined by the 
author. The articles are included if they contain 
original data from the group, clinical trials, case series, 
patients undergoing serum S100B levels with both 
short and long-term follow-up mortality. Only English 
language journals and full text are included in this 
study. Data extracted from the study included using 
data extraction forms. The scope of data collection is 
about the place of study, method, number of mortality, 
serum S100B levels, and the diagnostic strength of 
serum S100B levels. The primary parameter of this 
study was the difference in S100B levels in patients 
who died and living head injuries. Secondary 
parameters are the diagnostic strength of serum 
S100B levels. 
This meta-analysis will calculate the 
difference in mean serum S100B levels in subjects 
who died and lived head injuries with follow-up during 
treatment, 24 hours, 3 months, 6 months, and 1 year. 
Data were analysed by Review Manager 5.3 
(Cochrane Collaboration, Copenhagen, Denmark) and 
the significance limit was 0.05. 
 
Results 
 
The study results yielded 9 studies to be 
analysed [10] [12] [13] [16] [17] [18] [19] [20] [21] 
(Table 1) which can be included in the study. The 
article searching process was carried out based on 
the PRISMA principle (Figure 1). In this meta-analysis, 
we will assess the difference in S100B levels in 
survived and dead subjects with traumatic brain injury. 
Also, the diagnostic strength of serum S100B levels 
will also be explained. 
 
Figure 1: Flowchart PRISMA showed journal method of selection 
 
Differences in serum S100B levels between 
survived and dead subjects based on follow-up time. 
Overall, from the meta-analysis of the 11 
studies, the mean difference calculated from random 
effects showed significant results (p < 0.001). 
 
Figure 2: Forest plot difference of S100B serum levels in survived 
and died subjects based on follow up the timeline (a) overall, (b) 
within treatment, (c) 6 months 
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The total mean difference of serum S100B 
level before and after traumatic brain injury was 
significant statistically (0.91; 95%CI 0.7-1.12, I
2
 = 
98%, p < 0.001; Figure 2a). If classified based on the 
length of follow-up time until, during treatment, there 
were 5 studies reviewed. From the meta-analysis of 
the five studies, the random effects mean difference 
showed significant results (p < 0.001). The total mean 
difference was 1.43 (95% CI 0.97-1.89, I
2 
= 98%, p < 
0.001; Figure 2b). For up to 5 months of follow-up, 
from the three studies, the random effects mean 
difference also showed significant results (p < 0.001). 
The total mean difference was 0.19 (95% CI 0.1-0.29, 
I
2
 = 76%, p < 0.001; Figure 2c). In the study with a 
follow-up period of 24 hours, 3 months, and 1 year, 
there was only 1 study in each study (Table 1). 
Table 1: Studies included in this meta-analysis based on follow 
up time 
Study, year Country Methods 
Time of follow 
up 
Mortality Mean value of S100B 
During hospital stay 
Rodriguez et al., 
2012
16
 
Finland ECLIA Inpatient 10/55 
S: 0.3 ± 0.2 ug/L 
D: 1.7 ± 1.2 ug/L 
C: 0,461 ug/L 
AUC: 0,958 
Sens: 90% 
Spe: 88,4% 
Shakeri et al., 
2015
13
 
Iran ELISA Inpatient 30/72 
S: 1.04 ± 0.5 ug/mL 
D: 2.36 ± 0.94 ug/mL (p<0.001) 
Pfortmueller et al., 
2016
10
 
Austria ELISA Inpatient 52/1367 
D: 8.2 ± 3.5 ug/L 
S: 2.2 ± 0.8 ug/L 
(p < 0.001) 
C: 2 ug/L 
Rodriguez et al., 
2016
17
 
Finland ECLIA Inpatient 
15/99 
 
S: 0.09 ± 0.03 ug/L 
D: 0.36 ± 0.2 ug/L 
C: 0.2 ug/L 
(p = 0.003) 
AUC: 0.848 
Sens: 86,7% 
Spe: 75% 
Duda et al., 2017
18
 Polandia ELISA Inpatient 22/62 
S: 0.08 ± 0.03 ug/L 
D: 0.6 ± 0.04 ug/L 
C: 0.12 ug/L 
Sens: 50% 
Spe: 90% 
11/22 showed S100B higher 
than 0.12 ug/L 
24 Hours      
Rainey et al., 
2009
12
 
UK ELISA 24 hours 30/100 
S: 0.59 ± 0.23 ug/L 
D: 1.44 ± 0.84 ug/L 
C: 0.53 ug/L 
AUC: 0.69 
Sens: 82% 
Spe: 60% 
3 Months      
Olivecrona et al., 
2009
19
 
Swedia LIA 
3 months 
 
6/48 
 
S: 0,6 ± 0,2 ug/L 
D: 2,38 ± 0,8 ug/L 
AUC: 0,687 
Sens: 100% 
Spe: 38,1% 
C: 0.51 ug/L 
6 Months      
Ballesteros et al., 
2018
20
 
Spain ECLIA 6 months 46/83 
S: 0.15 ± 0.05 ug/L 
D: 0.3 ± 0.15 ug/L 
AUC: 0.739 
Rodriguez et al., 
2016
17
 
Finland ECLIA 6 months 19/99 
S: 0.09 ± 0.03 ug/L 
D: 0.28 ± 0.12 ug/L 
(p=0.002) 
C: 0.177 ug/L 
AUC: 0.855 
Sens: 89.5% 
Spe: 76.2% 
Gradisek et al., 
2012
21
 
Slovenia ELISA 1 year 26/73 
S: 0.77 ± 0.6 ug/L 
D: 1.565 ± 1.1 ug/L 
ug/L(p<0.001) 
1 Year      
Olivecrona et al., 
2009
19
 
Swedia LIA 1 year 
8/48 
 
S: 0.8 ± 0.3 ug/L 
D: 3 ± 1.2 ug/L 
AUC: 0.647 
Sens: 87.5% 
Spe: 37.5% 
C: 0.51 ug/L 
S: Survived, D: Died, AUC: Area Under Curve: Sens: Sensitivity, Spe: Specificity, C: Cut off. 
 
The diagnostic strength of serum S100B 
levels in predicting early and late 
mortalities in subjects with a head injury 
In this study, early mortality biomarkers were 
determined in samples which were taken during 
treatment or in the first 24 hours. The mean sensitivity 
of the four studies showed that the threshold value of 
S100B in the predicting short-term mortality was 0.328 
± 0.198 μg/L. The mean sensitivity was 77.18 ± 
18.41%, and specificity was 78.35 ± 13.96%. Of the 
five studies, only three reported the results of AUC, 
with the mean AUC obtained from the four studies 
was 0.832 ± 0.134. 
In this study, the final mortality predictions 
were taken with a follow-up period of more than 1 
month. The mean sensitivity of the four studies 
showed that the threshold value of S100B in the 
prediction of short-term mortality was 0.399 ± 0.19 
μg/L. The mean sensitivity was 92.33 ± 6.71%, and 
specificity was 50.6 ± 22.17%. Of the four studies, 
only three reported the results of AUC, so that the 
mean AUC obtained from the four studies was 0.732 ± 
0.09. 
From the graph plotted regarding the S100B 
threshold value that predicts mortality during long-
term care and mortality in 3-6 months, it was shown 
that the median value of the graph was approximately 
0.5 μg/L (Figure 3). 
 
Figure 3: Cut off point of S100B serum levels which were taken 
during a hospital stay, 24 hours, 1 month, 3 months, 6 months, and 
1 year 
 
 
 
Discussion 
 
Mortality rates due to TBI vary in several 
studies. Some studies also use different time methods 
and parameters to analyse this mortality. The fatality 
rate for TBI ranges from 13-22% [22]. After primary 
traumatic brain injury, secondary traumatic brain injury 
will continue in a few minutes, days, months, and 
years after primary traumatic brain injury due to 
excess metabolic, cellular and molecular inflammation 
activity [23]. 
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S100 is a small dimeric cytosolic protein, 9-21 
kDa, in the form of a homodimer with solubility in 
100% ammonium sulfate liquid with a helical-loop-
helical calcium bond [24]. S100B gene can be 
mapped on the long arm of chromosome 21q22.3. 
The S100B level is generally stable, not affected by 
storage, centrifugation, and temperature changes 
which will greatly facilitate sampling and reliability 
techniques in the analysis [25]. 
In TBI, S100B can be secreted into the 
systemic circulation along with the blood-brain barrier 
[26]. In the initial TBI phase, S100B is secreted as a 
TBI compensator with the effects of neurotrophic 
agents which have neuromodulating action and 
support the memory and thinking process [27]. In the 
final phase, where inflammation has been very high, 
and the blood-brain barrier has been disrupted, 
S100B acts as a destructor of neurons due to 
stimulation of proinflammatory cytokines and free 
radical activity which is often found in the 
pathophysiology of neurodegenerative disorders [28]. 
S100B as a TBI biomarker was first put 
forward in 1995 [29] where high S100B concentrations 
can be a primary and secondary TBI biomarker [30]. 
Researchers also found that this biomarker can be a 
TBI severity stratification based on GCS [31]. The 
ability of S100B in TBI output prediction has made 
some The researchers concluded that this biomarker 
was available as a predictor of TBI early and late 
diagnosis and mortality. From this meta-analysis, it 
was shown that high level of S100B was significantly 
different in the survive or died subjects with head 
injuries. The strength of short-term mortality predictors 
is also better than long-term mortality both from the 
significance of mean differences and diagnostic 
strength. 
In another study, Unden in 33 patients (13%) 
showed that S100B could predict adverse outcomes 
(p = 0.03) but not mortality (p = 0.182) [32]. Shakeri et 
al., (2013) opposed the results that the level of S-
100B could not be a predictor of mortality. The 
differences were due to variations in the time of 
collection of S100B in each study, ranging from the 
time of trauma to 84 hours after trauma. Research 
also takes heterogeneous long-term results between 1 
month to several years so that the results of the study 
are also varied [13]. 
The weakness of this meta-analysis was not 
separating research based on varied sampling times. 
The optimal time for S100B sampling is still a warm 
discussion. Existing studies show different retrieval 
times [8]. In some studies, it was shown that the 
earlier sample was better [33]. However, some 
showed that the sample after 6 hours was better [34]. 
Some suggested 6-12 hours [3], 12 hour [35], 24 
hours [36], 48 hours [37], 72 hours [11], and 84 hours 
[38]. 
The threshold value of serum S100B is still 
controversial. The wide range is shown by several 
studies. In this meta-analysis, the threshold value of 
S100B varies greatly depending on the method used. 
Although, the graph showed that the value is around 
0.5 μg/L. Meta-analysis of Mercier et al., [8] on 39 
studies in 1862 patients showed that serum S100B 
levels between 2.16-14.0 μg/L were effective for 
predicting adverse outcomes and mortality. Recently, 
a study of 3,893 patients showed a higher threshold 
value of 0.16-0.20 μg/L with a specificity of 51% for 
detecting intracranial abnormalities [11]. However, 
other clinicians stated that the threshold value lower 
than 0.1 μg/l was better for preventing false-negative 
cases, especially in epidural hematomas which 
usually indicate low S100B levels [16]. Unden et al., 
[32] did not find EDH subjects with S100B serum level 
higher than 0.14 μg/l [31]. Wolf et al., [39] have shown 
that the threshold value of S100B, 0.1 μg/l was found 
to be effective for detecting epidural hematoma at the 
initial presentation. 
Giving the above results, it can be concluded 
that S100B serum level is very potential in predicting 
mortality due to traumatic brain injury. For further 
research, S100B biomarkers could be analysed in 
salivary and urine, which are useful as diagnostic 
markers. Urine and saliva samples could be obtained 
noninvasively so that they have the potential to be 
applied. 
In conclusion, there is a significant difference 
in the mean serum S100B levels between patients 
who survived and died after traumatic brain injury. The 
diagnostic strength of serum S100B levels is 
promising in predicting mortality with a range of 
threshold values that vary according to the 
examination method used. S100B levels in the future 
will be a future potential biomarker, and it is expected 
that there will be a standardised guideline for its 
application. 
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